Menu Close

Trending

Huge inequalities found in access to myeloma clinical trials in Europe, says MPE
6th Annual 3D Cell Culture Conference
SMC gives Bayer’s CKD therapy Kerendia the green light in Scotland
Can VR technology make physical therapy fun? – the pharmaphorum podcast
Steps to building a more patient-centric industry

ES-SCLC

NICE1

Market Access/ News/ News/ News/ Oncology/ Top stories

NICE recommends Roche’s Tecentriq in ES-SCLC following price rethink

, , , , , , 0 Comment

NICE has said that Roche’s Tecentriq (atezolizumab) plus chemotherapy should be funded by the NHS as an option for untreated extensive-stage small-cell

X
NICE recommends Roche’s Tecentriq in ES-SCLC following price rethink
https://pharmaphorum.com/news/nice-recommends-roches-tecentriq-in-es-sclc-following-price-rethink/

Login

CONTINUE TO SITE >
X
Close in 10 seconds